AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$IRIX

Dizon Romeo R purchased $5K of IRIX

Dizon Romeo R (Chief Financial Officer) purchased 6,668 shares of IRIDEX CORP (IRIX) at an average of $0.75 ($0.75–$0.75) across 2 trades on 2026-08-24.

Original reporting
SEC EDGAR · Dizon Romeo R
Published Aug 24, 2026, 4:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 4:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRIX
Neutral
high confidence
Mentioned
$IRIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRIXNeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock materially.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming product announcements not disclosed.

Relevance 4/10Novelty 3/10Timing: 2026-08-24 filing

Background

Form 4 filings disclose insider trades; CFO purchases are monitored for sentiment.

Company-level read

Ticker impact

$IRIXNeutralHigh confidence
Context

CFO Dizon Romeo purchased 6,668 shares for $4,999, a direct insider buy.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Transaction size is modest relative to float and typical insider activity.

Market effects

Sector

None significant for ophthalmic device sector.

Regional

No regional effect.

Global

Limited to IRIDEX shareholders.

Counterpoint

What could challenge this read

Insider buying could be a subtle bullish sign despite small size.

Key entities

  • company
    IRIDEX CORP

    Medical device company listed on NASDAQ (IRIX).

  • person
    Dizon Romeo R

    Chief Financial Officer of IRIDEX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRIX insider trading history →

Related articles

AUG 19
$IRIXMed

IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company

IRIDEX Corp (IRIX) reported Q2 2026 earnings, highlighting a 35% surge in Cyclo-G6 probe sales. CEO Patrick Mercer expects low single-digit retina growth for the year, driven by regulatory approvals and promotions, despite headwinds in the Middle East and China. The company placed fewer Cyclo-G6 systems due to regulatory delays but anticipates higher numbers in Q4. Glaucoma growth was broad-based, with strong US and international performance. Revenue decline was attributed to retina business and

yahoo.com2 min
AUG 18
$IRIXMed

IRIDEX CORP (IRIX): Results of Operations and Financial Condition

IRIDEX CORP (IRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for

SEC EDGAR 8-K6 min